Neurology startup Magnolia Neurosciences raises $31M in Series A round
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer's disease.
In a busy field, biotech incubators are evolving
Life science incubators and accelerators are expanding and broadening their value-adds, as highlighted on Thursday by two significant announcements; one from Boston, one from Israel.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Past the pill and product: What do VCs want?
During a panel at MedCity INVEST, four experts addressed what VCs and potential acquirers are looking for in emerging companies.
What does J&J’s restructuring, job cuts demonstrate about the status of medical device market growth?
The market for medical devices is still growing, but has gone way down in the past decade. Johnson & Johnson's restructuring plan appears to be a direct reflection of the numbers.
Meet the Mt. Rushmore of healthcare corporate venture capital
Throughout the year Lake Whillans, with the help of MedCity News, has explored two key issues for healthcare investors and entrepreneurs: trust and reliability. We’ve helped bring to light some harrowing war stories of partnerships gone bad. We’ve also asked healthcare leaders in the trenches about the best ways to operate in the modern healthcare […]